These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 9759593)
1. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis. Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593 [TBL] [Abstract][Full Text] [Related]
2. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B; Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104 [TBL] [Abstract][Full Text] [Related]
3. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Niederau C; Backmerhoff F; Schumacher B; Niederau C Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126 [TBL] [Abstract][Full Text] [Related]
4. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Folwaczny C; Wiebecke B; Loeschke K Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024 [TBL] [Abstract][Full Text] [Related]
5. [The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease]. López Morante AJ; Sáez-Royuela F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C Rev Esp Enferm Dig; 1993 Jan; 83(1):5-9. PubMed ID: 8452705 [TBL] [Abstract][Full Text] [Related]
6. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease. Griga T; May B; Pfisterer O; Müller KM; Brasch F Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933 [TBL] [Abstract][Full Text] [Related]
8. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Kapsoritakis AN; Koukourakis MI; Sfiridaki A; Potamianos SP; Kosmadaki MG; Koutroubakis IE; Kouroumalis EA Am J Gastroenterol; 2001 Mar; 96(3):776-81. PubMed ID: 11280550 [TBL] [Abstract][Full Text] [Related]
9. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117 [TBL] [Abstract][Full Text] [Related]
10. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192 [TBL] [Abstract][Full Text] [Related]
11. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Pimentel M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC Am J Gastroenterol; 2000 Dec; 95(12):3458-62. PubMed ID: 11151877 [TBL] [Abstract][Full Text] [Related]
12. Elevated thrombopoietin serum levels in patients with inflammatory bowel disease. Kapsoritakis AN; Potamianos SP; Sfiridaki AI; Koukourakis MI; Koutroubakis IE; Roussomoustakaki MI; Manousos ON; Kouroumalis EA Am J Gastroenterol; 2000 Dec; 95(12):3478-81. PubMed ID: 11151880 [TBL] [Abstract][Full Text] [Related]
13. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Griga T; Voigt E; Gretzer B; Brasch F; May B Hepatogastroenterology; 1999; 46(26):920-3. PubMed ID: 10370639 [TBL] [Abstract][Full Text] [Related]
14. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease]. Vucelić B; Krznarić Z; Sentić M; Milicić D; Korać B; Cvorisćec D; Stavljenić A Lijec Vjesn; 1990; 112(9-10):281-4. PubMed ID: 2093781 [TBL] [Abstract][Full Text] [Related]
15. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease. Nielsen OH; Brynskov J; Bendtzen K Dan Med Bull; 1993 Apr; 40(2):247-9. PubMed ID: 8495600 [TBL] [Abstract][Full Text] [Related]
16. Abnormalities of fasting serum concentrations of peptide YY in the idiopathic inflammatory bowel diseases. Koch TR; Roddy DR; Go VL Am J Gastroenterol; 1987 Apr; 82(4):321-6. PubMed ID: 3565336 [TBL] [Abstract][Full Text] [Related]